BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter of fiscal 2023 ended December 31, 2022.

ProSomnus, Inc., a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea, announced certain unaudited results for the quarter and full year ended December 31, 2022.

St. Luke’s Health and its academic affiliate Baylor College of Medicine are back in-network with Cigna, adding the insurer to a large group of in-network carriers.

Vera Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 14,285,715 shares of its Class A common stock at a price to the public of $7.00 per share.

Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), has filed its financial results for the first three quarters of the 2023 fiscal year.

Tyber Medical LLC has acquired 100 percent of the capital of ADSM-Synchro Medical, a French orthopedic medical device company, specializing in the development and distribution of implants dedicated to treating surgical forefoot pathologies.

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that the first patient has been dosed in the United States in its Phase 1/2 clinical trial evaluating AU-007 for the treatment of solid tumors.

Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

Recently, the California Institute of Regenerative Medicine (CIRM) awarded Greenstone Bio $675,000 to find novel treatments for Duchenne Muscular Dystrophy (DMD), a fatal genetic disease with no current cure.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will participate in the following investor conferences in February.